Routine upstream versus selective down stream use of tirofiban in non-ST elevation myocardial infarction patients scheduled for early invasive therapy; a randomized comparison

Journal of Thrombosis and Thrombolysis

Volumn 24, Issue 3, 2007, Pages 241-246

  Rasoul, Saman ^a   Ottervanger, Jan Paul ^a   de Boer, Menko Jan ^a   Dambrink, Jan Henk E ^a   Suryapranata, Harry ^a   Hoorntje, Jan C A ^a   Gosselink, A T Marcel ^a   van 't Hof, Arnoud W J ^a  

^a Isala Klinieken ^*  (Netherlands)

Author keywords

Antithrombotic therapy; Glycoprotein IIb IIIa inhibitor; Non ST segment elevation ACS; Tirofiban

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CLOPIDOGREL; CREATINE KINASE; CREATINE KINASE MB; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTATE DEHYDROGENASE; TIROFIBAN; TROPONIN T;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; DRUG FATALITY; FEMALE; HEART INFARCTION; HEART TAMPONADE; HUMAN; INVASIVE PROCEDURE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SINGLE DRUG DOSE; ST SEGMENT DEPRESSION;

AGED; CORONARY ANGIOGRAPHY; CREATINE KINASE; DRUG ADMINISTRATION ROUTES; ELECTROCARDIOGRAPHY; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; TYROSINE;

EID: 35448948230     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-007-0015-y     Document Type: Article

References (18)

1. Silber S, Albertsson P, Aviles FF, Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology et al (2005) Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 26:804-847
2. Braunwald E, Antman E, Beasley J et al (2000) ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol 36:970-972
3. Roffi M, Chew DP, Mukherjee D et al (2002) Platelet glycoprotein IIb/ IIIa inhibition in acute coronary syndromes: Gradient of benefit related to the revascularization strategy. Eur Heart J 23:1441-1448
4. van 't Hof AWJ, de Vries ST, Dambrink JHE et al (2003) A comparison of two invasive strategies in patients with non-ST elevation acute coronary syndromes: Results of the Early or Late Intervention in unStable Angina (ELISA) pilot study. IIb/IIIa upstream therapy and acute coronary syndromes. Eur Heart J 24:1401-1405
5. Rasoul S, Ottervanger JP, de Boer MJ et al (2006) A comparison of dual versus triple antiplatelet therapy in patients with non ST segment elevation acute coronary syndromes. Results of the ELISA-2 trial. Eur Heart J 27:1401-1407
6. Chesebro JH, Knatterud G, Roberts R et al (1987) Thrombolysis In Myocardial Infarction (TIMI) trial, phase 1: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 76:723-725
7. Zhao X-Q, Theroux P, Snapinn SM, Sax FL (1999) Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with Tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators. Circulation 100:1609-1615
8. Gibson CM, Singh KP, Murphy SA, TIMI Study Group et al (2004) Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy). Am J Cardiol 94:492-494
9. Bolognese L, Falsini G, Liistro F et al (2006) Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: The EVEREST trial. J Am Coll Cardiol 47:522-528
10. Kastrati A, Mehilli J, Neumann FJ et al (2006) Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: The ISAR-REACT 2 randomized trial. JAMA 295:1531-1538
11. Stone G (2006) ACUITY TIMING, presented at American college of Cardiology. Available at: http://acc06online.acc.org/ Lectures.aspx?sessionId=67&date=13
12. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med (1998) 338:1488-1497
13. Glaser R, Glick HA, Herrmann HC, Kimmel SE (2006) The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: A cost-effectiveness analysis. J Am Coll Cardiol 47:529-537
14. Goto S, Tamura N, Ishida H (2004) Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. J Am Coll Cardiol 44:316-323
15. Pieper KS, Tsiatis AA, Davidian M et al (2004) Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus medical therapy for acute coronary syndromes: Exploration of methods. Circulation 109:641-646
16. Giugliano RP, Newby LK, Harrington RA, EARLY ACS Steering Committee et al (2005) The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: A randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome-study design and rationale. Am Heart J 149:994-1002
17. Januzzi JL, Chae CU, Sabatine MS, Jang IK (2001) Elevation in serum troponin I predicts the benefit of tirofiban. J Thromb Thrombolysis 11:211-215
18. Roe MT, Christenson RH, Ohman EM, EARLY Investigators; Emergency Medicine Cardiac Research and Education Group et al (2003) A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes. Am Heart J 146:993-998